LINE ITEM / 08
About this GHK-Cu research ledger
An independent editorial project that reads the published copper-tripeptide literature as an audited record — what is verified, what is preclinical, and where the human data simply does not exist.
What this site is
Legal GHK-Cu is an independent editorial project that publishes summaries of the peer-reviewed research literature on GHK-Cu, the glycyl-histidyl-lysine copper(II) complex. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.
The site reads GHK-Cu the way a financial statement reads an account — each finding posted as a line item, each number reconciled to its primary source, each regulatory status marked with its own status. That framing is editorial, chosen because the GHK-Cu literature is unusually quantitative and unusually mixed in evidence grade: it deserves an honest ledger more than a brochure.
What 'legal' means here
The word 'legal' in this site's name is editorial framing, not a claim about services. It refers to a real and specific distinction in the record: topical Copper Tripeptide-1 is a legal cosmetic ingredient in the US, EU and UK with a long market safety history, while injectable or systemic GHK-Cu is an unapproved research chemical with no validated human pharmacokinetics and no approved regulatory pathway [3]. There is no FDA- or EMA-approved drug product for GHK-Cu by any route [3].
The site does not offer treatment, consultation, prescriptions or product sales of any kind, and nothing here should be read as encouragement to use GHK-Cu in any form. We summarize what studies measured and where the regulatory lines fall; decisions and medical questions belong with qualified professionals, not with a literature digest.
How the record is sourced
Every quantitative claim on this site — every dose, percentage, count, half-life and concentration — is tied to a numbered citation that resolves to a PubMed, PMC or DOI source on the references page. Where a study used the free GHK peptide rather than the copper complex, the entry says so, because the two are not interchangeable in the evidence [3][6]. Where the evidence is in-vitro or rodent rather than human, the body text marks the grade rather than implying more than the data supports.
We also post the limitations as line items. The bulk of the foundational mechanism and review literature comes from a single investigator group, independent replication of the broader gene-expression claims is limited, and there is no validated human pharmacokinetic data for systemic use [3]. An audited ledger that hid its caveats would not be audited at all.